一项前瞻性、多中心临床试验评估Cerene装置治疗月经过多的安全性和有效性
这项前瞻性、多中心、单臂、开放标签、非随机研究在北美11个中心纳入242例因良性原因月经过多的绝经前女性,评估Cerene冷冻消融装置的安全性和有效性。结果显示无装置或操作相关严重不良事件,月经失血量评分从治疗前平均360.6降至12个月时51,81%可评估受试者PBLAC评分≤75,90%报告满意或非常满意。
要点
- Cerene冷冻消融装置对子宫内膜给予2.5分钟治疗,未发生装置或操作相关严重不良事件。
- 治疗前PBLAC平均评分360.6降至12个月时51,81%可评估者PBLAC≤75。
- 仅3%受试者使用静脉镇静,无全身麻醉,治疗期间中位疼痛评分≤2(轻度)。
核心结论
- Cerene冷冻消融安全有效,可减少月经失血量、限制止痛药使用、患者耐受性高、改善生活质量并保留子宫腔通路。
研究设计与样本
- 前瞻性、多中心、单臂、开放标签、非随机研究,在北美11个学术和私人诊所开展,包括美国8个诊所点和墨西哥1个、加拿大2个门诊医院点。
- 意向治疗人群共242例受试者,受试者人口学特征与已发表的其他子宫内膜消融研究相似。
主要发现
- 无装置或操作相关严重不良事件,也无非预期不良装置效应。
- PBLAC平均评分从治疗前360.6(±332.1)降至治疗后12个月51(±64.1),230例可评估受试者中81%报告PBLAC评分≤75,85%可评估受试者报告PBLAC评分≤100。
- 治疗全程中位疼痛评分≤2(轻度)。
- 12个月时223例受试者接受宫腔镜检查,其中220例可窥见子宫腔。
- 12个月时90%报告受试者表示满意或非常满意,生活质量改善。
关键数值与推荐
- 单次使用一次性冷冻消融装置(Cerene)对子宫内膜给予2.5分钟治疗。
- 镇痛和局部麻醉由研究者酌情给予;仅3%受试者使用静脉镇静,无全身麻醉使用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY OBJECTIVE: To evaluate the safety and effectiveness of a novel cryoablation device (Cerene Cryotherapy Device, Channel Medsystems, Emeryville, CA) in premenopausal women with heavy menstrual bleeding owing to benign causes. DESIGN: A prospective, multi-center, single-arm, open label, non-randomized study. SETTING: At 11 academic and private practices in North America: 8 clinic sites in the United States, and 3 outpatient hospital sites (1 in Mexico and 2 in Canada). PATIENTS: A total of 242 subjects comprise the intent-to-treat population. Subject demographics were similar to other published endometrial ablation studies performed. INTERVENTIONS: Subjects were treated with a single-use disposable cryoablation device (Cerene) which delivers a 2.5-minute treatment to the endometrium. Analgesia and local anesthesia were administered per investigator discretion; intravenous sedation was used in only 3% of subjects and no general anesthesia was used. MEASUREMENTS AND MAIN RESULTS: There were no device or procedure-related serious adverse events, nor unanticipated adverse device effects. Cerene cryoablation was effective in reducing menstrual blood loss, which was measured by pictorial blood loss assessment chart (PBLAC) score. Mean score dropped from 360.6 at pretreatment (±332.1) to 51 at 12 months posttreatment (±64.1), with 81% of 230 evaluable subjects reporting a PBLAC score of ≤75 and 85% of evaluable subjects reporting a PBLAC score of ≤ 100. The median pain rating was ≤2 (mild) throughout the treatment. Of 223 subjects that underwent hysteroscopic evaluation at 12 months, the uterine cavity was visualized in 220 subjects. Quality of life improved with 90% of reporting subjects indicating satisfied or very satisfied at month 12. CONCLUSION: This study demonstrated that Cerene cryoablation is safe and effective, offering the benefits of reduced menstrual blood loss with limited use of pain medication, high patient tolerability, quality of life improvement, and preserved access to the uterine cavity.
引用
- Curlin HL, Cintron LC, Anderson TL, et al. A Prospective, Multicenter, Clinical Trial Evaluating the Safety and Effectiveness of the Cerene Device to Treat Heavy Menstrual Bleeding. J Minim Invasive Gynecol. 2020. PMID: 32835865. doi:10.1016/j.jmig.2020.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。